DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Ellison DH. Diuretic resistance: Physiology and therapeutics.
Semin Nephrol, 1999, 19:581–597.
Erwin PA, Lin AJ, Golan DE, Michel T. Receptor- regulated
dynamic S- nitrosylation of endothelial nitric- oxide synthase in
vascular endothelial cells. J Biol Chem, 2005, 280:19888–19894.
Farquharson CA, Struthers AD. Spironolactone increases nitric
oxide bioactivity, improves endothelial vasodilator dysfunction,
and suppresses vascular angiotensin I/angiotensin II conversion
in patients with chronic heart failure. Circulation,
2000, 101:594–597.
Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory
responses to digitalis glycosides in heart failure patients.
Direct evidence from sympathetic neural recordings.
Circulation, 1989, 80:65–77.
Feron O, Dessy C, Desager JP, et al.Hydroxy-methylglutarylcoenzyme
A reductase inhibition promotes endothelial nitric
oxide synthase activation through a decrease in caveolin abundance.
Circulation, 2001, 103:113–118.
Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin
antagonists for the treatment of heart failure and hyponatremia.
Circulation, 2008, 118:410–421.
Fonarow GC, Chelimsky- Fallick C, Stevenson LW, et al. Effect
of direct vasodilation with hydralazine versus angiotensinconverting
enzyme inhibition with captopril on mortality in
advanced heart failure: The Hy- C trial. J Am Coll Cardiol,
1992, 19:842–850.
Francis GS, Benedict C, Johnstone DE, et al. Comparison of
neuroendocrine activation in patients with left ventricular dysfunction
with and without congestive heart failure. A substudy
of the Studies of Left Ventricular Dysfunction (SOLVD).
Circulation, 1990, 82:1724–1729.
Frey R, Mück W, Unger S, et al. Pharmacokinetics, pharmacodynamics,
tolerability, and safety of the soluble guanylate
cyclase activator cinaciguat (BAY 58-2667) in healthy male
volunteers. J Clin Pharmacol, 2008, 48:1400–1410.
Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of
tolvaptan, a vasopressin antagonist, in patients hospitalized
with worsening heart failure: A randomized controlled trial.
JAMA, 2004, 291:1963–1971.
Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term
clinical effects of tolvaptan, an oral vasopressin antagonist, in
patients hospitalized for heart failure: The EVEREST Clinical
Status Trials. JAMA, 2007, 297:1332–1343.
GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate
singly and together on 6-week mortality and ventricular function
after acute myocardial infarction. Gruppo Italiano per lo
Studio della Sopravvivenza nell’infarto Miocardico. Lancet,
1994, 343:1115–1122.
Givertz MM, Massie BM, Fields TK, et al. The effects of KW-
3902, an adenosine A 1
-receptor antagonist, on diuresis and
function in patients with acute decompensated heart failure
and renal impairment or diuretic resistance. J Am Coll Cardiol,
2007, 50:1551–1660.
Goldstein JL, Brown MS. Regulation of the mevalonate pathway.
Nature, 1990, 343:425–430.
Gottlieb SS. Management of volume overload in heart failure.
In: Mann DL, ed. Heart Failure: A Companion to Braunwald’s
Heart Disease. Saunders, Philadelphia, 2004, pp. 595–602.
Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an
A 1
adenosine receptor antagonist, protects against the decline
in renal function observed with diuretic therapy. Circulation,
2002, 105:1348–1353.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of β- blockade on
mortality among high- risk and low- risk patients after myocardial
infarction. N Engl J Med, 1998, 339:489–497.
Hall SA, Cigarroa CG, Marcoux L, et al. Time course of
improvement in left ventricular function, mass and geometry
in patients with congestive heart failure treated with β-
adrenergic blockade. J Am Coll Cardiol, 1995, 25:1154–1161.
Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised
study of effect of ibopamine on survival in patients with
advanced severe heart failure. Second Prospective Randomised
Study of Ibopamine on Mortality and Efficacy (PRIME II)
Investigators. Lancet, 1997, 349:971–977.
Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in
patients with symptomatic heart failure. J Am Coll Cardiol,
2008, 51:2301–2309.
Hernandez- Perera O, Perez- Sala D, Navarro- Antolin J, et al.
Effects of the 3-hydroxy-3- methylglutaryl- CoA reductase
inhibitors, atorvastatin and simvastatin, on the expression of
endothelin-1 and endothelial nitric oxide synthase in vascular
endothelial cells. J Clin Invest, 1998, 101:2711–2719.
Hillege HL, Girbes AR, deKam PJ, et al. Renal function, neurohumoral
activation, and survival in patients with chronic heart
failure. Circulation, 2000, 102:203–210.
Horwich TB, MacLellan R, Fonarow GC. Statin therapy is associated
with improved survival in ischemic and non- ischemic
heart failure. J Am Coll Cardiol, 2004, 43:642–648.
Jessup M, Brozena S. Heart failure. N Engl J Med, 2003,
348:2007–2018.
Jones R, Francis GS, Lauer MS. Predictors of mortality in
patients with heart failure and preserved systolic function in
The Digitalis Investigation Group trial. J Am Coll Cardiol,
2004, 44:1025–1029.
Kamezaki F, Tasaki H, Yamashita K, et al. Angiotensin receptor
blocker improves coronary flow velocity reserve in hypertensive
patients: Comparison with calcium channel blocker.
Hypertens Res, 2007, 30:699–706.
Kasama S, Toyama T, Sumino H, et al. Additive effects of
spironolactone and candesartan on cardiac sympathetic nerve
activity and left ventricular remodeling in patients with congestive
heart failure. J Nucl Med, 2007, 48:1993–2000.
Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5:
Expanding roles in cardiovascular regulation. Circ Res, 2007,
101:1084–1095.
Kelly RA, Smith TW. Recognition and management of digitalis
toxicity. Am J Cardiol, 1992, 69:108G–119G.
Kittleson M, Hurwitz S, Shah MR, et al. Development of
circulatory-renal limitations to angiotensin-converting enzyme
inhibitors identifies patients with severe heart failure and early
mortality. J Am Coll Cardiol, 2003, 41:2029–2035.
Kjekshus J, Pedersen TR, Olsson AG. The effects of simvastatin
on the incidence of heart failure in patients with coronary heart
disease. J Card Fail, 1997, 3:249–254.
Koesling D. Studying the structure and regulation of soluble
guanylyl cyclase. Methods, 1999, 19:485–493.
Konstam MA, Neaton JD, Poole- Wilson PA, et al. Comparison
of losartan and captopril on heart failure- related outcomes and
symptoms from the losartan heart failure survival study
(ELITE II). Am Heart J, 2005, 150:123–131.
811
CHAPTER 28
PHARMACOTHERAPY OF CONGESTIVE HEART FAILURE